logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Aragon Pharmaceuticals, Inc.


USPTO Granted Patents = 35

% Expired Patents = 8.6



Forward Citations = 164

Loading Chart...
Loading Chart...

34 inventors (with patents filed for the assignee):

goldMedal Nicholas D Smith (15 out of 59 patents)

silverMedal Mark R Herbert (9 out of 13 patents)

bronzeMedal Ouathek Ouerfelli (8 out of 29 patents)

4.  Isan Chen (8 out of 10 patents)

5.  Anna Dilhas (6 out of 10 patents)

6.  Celine Bonnefous (5 out of 12 patents)

7.  Jackaline Dalgard Julien (5 out of 12 patents)

8.  Arturo Molina (3 out of 3 patents)

9.  Cyril Ben Haim (3 out of 6 patents)

10.  Andras Horvath (3 out of 17 patents)

11.  Johan Erwin Edmond Weerts (3 out of 10 patents)

12.  Jennifer Albaneze-Walker (3 out of 3 patents)

13.  Steven P Govek (2 out of 34 patents)

14.  Geert Verreck (2 out of 2 patents)

15.  Anna Dihas (2 out of 2 patents)


Core Competencies:
Anticancer Compositions
Anti-Androgens
Androgen Receptor Modulators
Castrate-Resistant Prostate Cancer
Metastatic Castration-Sensitive
Crystalline Forms
Diarylthiohydantoin Compound
Hepatic Impairment
Resistance Determination
Estrogen Receptor Modulators

35 patents:

1. 12746230 - Anticancer compositions (2026-09-29),
2. RE50642 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer (2025-10-21),
3. 12303497 - Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer (2025-05-20),
4. 12303493 - Anticancer compositions (2025-05-20),
5. 12018008 - Crystalline forms of an androgen receptor modulator (2024-06-25),
6. 11963952 - Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer (2024-04-23),
7. 11911511 - Anticancer compositions (2024-02-27),
8. 11723898 - Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment (2023-08-15),
9. RE49353 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer (2023-01-02),
10. 11491149 - Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer (2022-11-08),
11. 11224575 - Anticancer compositions (2022-01-18),
12. 11160796 - Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer (2021-11-02),
13. 11040953 - Process for the preparation of a diarylthiohydantoin compound (2021-06-22),
14. 10934271 - Crystalline forms of an androgen receptor modulator (2021-03-02),
15. 10849888 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer (2020-12-01),
Aragon Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer and other serious diseases. The company specializes in the discovery and advancement of novel drug candidates that target specific biological pathways, aiming to improve treatment outcomes for patients. With a commitment to scientific excellence, Aragon leverages cutting-edge research and technology to address unmet medical needs and enhance the quality of life for those affected by complex health conditions.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Aragon Pharmaceuticals, Inc.
35 Patents

#178 in San Diego, CA

#2,306 in California

#9,740 in US

#19,148 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Aragon Pharmaceuticals, Inc.

Forward Citations = 164

34 inventors:

goldMedal Nicholas D Smith (15 out of 59 patents)

silverMedal Mark R Herbert (9 out of 13 patents)

bronzeMedal Ouathek Ouerfelli (8 out of 29 patents)

4.  Isan Chen (8 out of 10 patents)

5.  Anna Dilhas (6 out of 10 patents)

Please report any incorrect information to [email protected]
Loading…